We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Testing Method Clinically Ascertains Genetic Basis for Hypercholesterolemia

By LabMedica International staff writers
Posted on 03 Nov 2016
Next-generation sequencing technology is transforming our understanding of heterozygous familial hypercholesterolemia, including revision of prevalence estimates and attribution of polygenic effects.

The use of next-generation sequencing (NGS) technology has pinpointed specific areas of a person's DNA to more effectively diagnose genetic forms of high-cholesterol, which markedly increase risk for heart attack and stroke.

Scientists at University of Western Ontario (London, ON, Canada) and their colleagues examined the contributions of monogenic and polygenic causes in patients with severe hypercholesterolemia referred to a specialty clinic. More...
They applied targeted next-generation sequencing with custom annotation, coupled with evaluation of large-scale copy number variation and polygenic scores for raised low-density lipoprotein cholesterol in a cohort of 313 individuals with severe hypercholesterolemia, defined as low-density lipoprotein cholesterol greater than 5.0 mmol/L (>194 mg/dL).

DNA samples were assessed by visualization on a 1% agarose gel and using a NanoDrop 1000 spectrophotometer, and the DNA was then and measured using a Qubit 2.0 fluorometer. The new genetic testing method called LipidSeq was able to identify a genetic mutation in 67% of the patients. They found that 54% were single gene mutations, and the other 13% were polygenic DNA variants, meaning they were a combination of multiple bad genes inherited together. The study also showed that the percentage of individuals with an identified genetic component increased as cholesterol levels in the patient increased. The percentage of individuals with an identified genetic component increased from 57.0% to 92.0% as low-density lipoprotein cholesterol level increased from 5.0 to >8.0 mmol/L (194 to >310 mg/dL).

Robert A. Hegele, MD, FRCPC, a professor of Endocrinology and the senior author of the study, said, “This new method provides a more cost-effective way to find these genetic links rather than sequencing the entire genome. By pre-identifying patients who have a personal and familial history of high-cholesterol, LipidSeq was able to find a genetic mutation in 67 % of those tested. This new method shows there is a benefit, especially when you can add the extra step of medically selecting those with a familial history of the disease.” LipidSeq has already been licensed for use in the USA to help clinicians identify patients with genetically-based high-cholesterol in order to guide drug prescriptions. The study was published on October 20, 2016, in the journal Arteriosclerosis, Thrombosis, and Vascular Biology.

Related Links:
University of Western Ontario



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.